Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | MDS updates from ASH 2019

David Steensma • 7 Dec 2019
ASH 2019
Myelodysplastic Syndromes APR-246 Azacitidine Magrolimab

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, shares his highlights in myelodysplastic syndromes (MDS) from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. These include the APR-246 (NCT03072043) and magrolimab (NCT03248479) trials, as well as studies of IDH inhibitors.

More from David Steensma

2:51
MDS and Agent Orange
David Steensma • 5 Mar 2020
0:43
MDS novel agents & HMAs
David Steensma • 5 Mar 2020
0:52
Azacitidine in the treatment of MDS
David Steensma • 5 Mar 2020
1:16
State of the art: MDS
David Steensma • 5 Mar 2020

Related Videos

2:06
Understanding the role of inflammation and the immunome in MDS pathophysiology
Shahram Kordasti • 5 Apr 2024
2:53
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti • 5 Apr 2024
2:37
Allo-SCT in older patients with MDS: selection, donors, and timing
Didier Blaise • 4 Apr 2024
1:08
Chronological age no longer dictates eligibility for allogeneic transplantation in patients with MDS
Didier Blaise • 4 Apr 2024
The content of VJHemOnc is intended for healthcare professionals